South Korea · Delayed Price · Currency is KRW JW Lifescience Statistics
Total Valuation
JW Lifescience has a market cap or net worth of KRW 170.64 billion. The enterprise value is 200.69 billion.
| Market Cap | 170.64B |
| Enterprise Value | 200.69B |
Important Dates
The next estimated earnings date is Friday, August 14, 2026.
| Earnings Date | Aug 14, 2026 |
| Ex-Dividend Date | Mar 31, 2026 |
Share Statistics
JW Lifescience has 15.48 million shares outstanding. The number of shares has decreased by -0.04% in one year.
| Current Share Class | 15.48M |
| Shares Outstanding | 15.48M |
| Shares Change (YoY) | -0.04% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 0.11% |
| Owned by Institutions (%) | 9.15% |
| Float | 8.56M |
Valuation Ratios
The trailing PE ratio is 5.85.
| PE Ratio | 5.85 |
| Forward PE | n/a |
| PS Ratio | 0.68 |
| PB Ratio | 0.78 |
| P/TBV Ratio | 1.20 |
| P/FCF Ratio | 4.93 |
| P/OCF Ratio | 3.60 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 3.86, with an EV/FCF ratio of 5.80.
| EV / Earnings | 6.88 |
| EV / Sales | 0.79 |
| EV / EBITDA | 3.86 |
| EV / EBIT | 6.02 |
| EV / FCF | 5.80 |
Financial Position
The company has a current ratio of 1.09, with a Debt / Equity ratio of 0.19.
| Current Ratio | 1.09 |
| Quick Ratio | 0.67 |
| Debt / Equity | 0.19 |
| Debt / EBITDA | 0.81 |
| Debt / FCF | 1.22 |
| Interest Coverage | 11.76 |
Financial Efficiency
Return on equity (ROE) is 13.98% and return on invested capital (ROIC) is 11.94%.
| Return on Equity (ROE) | 13.98% |
| Return on Assets (ROA) | 6.53% |
| Return on Invested Capital (ROIC) | 11.94% |
| Return on Capital Employed (ROCE) | 14.35% |
| Weighted Average Cost of Capital (WACC) | 5.69% |
| Revenue Per Employee | 850.91M |
| Profits Per Employee | 98.27M |
| Employee Count | 297 |
| Asset Turnover | 0.79 |
| Inventory Turnover | 5.65 |
Taxes
In the past 12 months, JW Lifescience has paid 2.84 billion in taxes.
| Income Tax | 2.84B |
| Effective Tax Rate | 8.86% |
Stock Price Statistics
The stock price has decreased by -8.61% in the last 52 weeks. The beta is 0.24, so JW Lifescience's price volatility has been lower than the market average.
| Beta (5Y) | 0.24 |
| 52-Week Price Change | -8.61% |
| 50-Day Moving Average | 12,048.40 |
| 200-Day Moving Average | 12,845.25 |
| Relative Strength Index (RSI) | 38.27 |
| Average Volume (20 Days) | 44,514 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, JW Lifescience had revenue of KRW 252.72 billion and earned 29.19 billion in profits. Earnings per share was 1,885.30.
| Revenue | 252.72B |
| Gross Profit | 72.89B |
| Operating Income | 33.36B |
| Pretax Income | 32.02B |
| Net Income | 29.19B |
| EBITDA | 51.99B |
| EBIT | 33.36B |
| Earnings Per Share (EPS) | 1,885.30 |
Balance Sheet
The company has 12.20 billion in cash and 42.25 billion in debt, with a net cash position of -30.05 billion or -1,940.61 per share.
| Cash & Cash Equivalents | 12.20B |
| Total Debt | 42.25B |
| Net Cash | -30.05B |
| Net Cash Per Share | -1,940.61 |
| Equity (Book Value) | 218.75B |
| Book Value Per Share | 14,126.88 |
| Working Capital | 7.02B |
Cash Flow
In the last 12 months, operating cash flow was 47.38 billion and capital expenditures -12.77 billion, giving a free cash flow of 34.61 billion.
| Operating Cash Flow | 47.38B |
| Capital Expenditures | -12.77B |
| Depreciation & Amortization | 18.62B |
| Net Borrowing | -24.95B |
| Free Cash Flow | 34.61B |
| FCF Per Share | 2,235.17 |
Margins
Gross margin is 28.84%, with operating and profit margins of 13.20% and 11.55%.
| Gross Margin | 28.84% |
| Operating Margin | 13.20% |
| Pretax Margin | 12.67% |
| Profit Margin | 11.55% |
| EBITDA Margin | 20.57% |
| EBIT Margin | 13.20% |
| FCF Margin | 13.70% |
Dividends & Yields
This stock pays an annual dividend of 500.00, which amounts to a dividend yield of 4.57%.
| Dividend Per Share | 500.00 |
| Dividend Yield | 4.57% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 26.53% |
| Buyback Yield | 0.04% |
| Shareholder Yield | 4.50% |
| Earnings Yield | 17.10% |
| FCF Yield | 20.28% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on April 20, 2018. It was a forward split with a ratio of 2.
| Last Split Date | Apr 20, 2018 |
| Split Type | Forward |
| Split Ratio | 2 |
Scores
JW Lifescience has an Altman Z-Score of 3.1 and a Piotroski F-Score of 5.
| Altman Z-Score | 3.1 |
| Piotroski F-Score | 5 |